# OnCo record paper-hahnen-geparsixto-germline-brca-jama-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-hahnen-geparsixto-germline-brca-jama-oncol-2017" ;
  schema:name "Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial"@en ;
  schema:description "In GeparSixto, 17% of triple-negative patients carried a germline BRCA1 or BRCA2 mutation; they responded well to chemotherapy whether or not carboplatin was added, while it was the non-carriers whose complete response rate rose from 36% to 55% with carboplatin."@en ;
  schema:url <https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2017.1007>, <https://pubmed.ncbi.nlm.nih.gov/28715532/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2017.1007> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Hahnen E, Lederer B, Hauke J, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:targets <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/gbg/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/geparsixto/> ;
  onco:people <https://onco.cc/people/sibylle-loibl/>, <https://onco.cc/people/carsten-denkert/>, <https://onco.cc/people/rita-schmutzler/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .